1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
SINIL PHARMACEUTICAL Co., Ltd.

SINIL PHARMACEUTICAL Co., Ltd.

KKRX:012790
6,140.00
KRW
-150.00
(-2.38%)
601.36EPS
9.84P/E
68.43BMarket Cap
SINIL PHARMACEUTICAL Co., Ltd.
KRX:012790
(Korea Stock Exchange)

Recent

price

6,140.00

P/E

ratio

9.84

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
3,117.78
2,909.51
3,444.18
3,822.9
4,153.4
3,857.13
4,330.6
4,392.86
4,595.71
5,231.97
5,306.52
5,334.38
6,916.74
7,710.35
7,736.56
6,964.2
7,109.51
Revenue per Share
340.53
268.4
383.25
631.85
877.86
756.15
807.29
706.95
492.88
626.04
651.61
576.92
1,051
1,180
1,237
651
601.36
Basic EPS, GAAP
465.69
160.73
250.78
593.23
541.75
324.57
840.23
427.7
532.14
436.32
223.75
650.83
376.84
193.24
1,230.12
616.67
384.09
Free Cash Flow per Basic Share
45.29
51.79
51.81
51.8
58.25
77.71
77.67
90.6
90.63
90.64
97.23
90.75
93.45
96.22
169.98
189.86
- -
Dividend per Share
4,265.34
4,477.27
4,749.68
5,363.05
6,111.67
6,743.29
7,236.23
7,843.78
8,210.71
12,226.83
9,550.53
10,069.36
11,082.32
11,669.56
12,673.99
13,179.53
13,303.78
Book Value per Share
4,112.22
4,139.93
4,382.48
5,038.94
5,759.41
6,369.53
7,097.09
7,738.29
8,111.07
12,089.75
9,433.25
9,909.14
10,914.2
11,512.97
12,523.79
12,973.46
13,099.8
Tangible Book Value per Share
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
Basic Weighted Avg Shares
36,162
33,729
39,911
44,311
48,160
44,703
50,212
50,942
53,277
60,648
61,438
61,754
80,007
89,135
89,440
80,564
82,183
Sales/Revenue/Turnover
11.24
10.56
13.58
21.45
25.46
23.52
20.94
18.14
11.3
15.52
11.1
12.93
17.07
15.7
17.02
9.17
8.21
Operating Margin (%)
1,649
1,531
1,754
2,078
2,088
2,463
2,929
3,328
3,678
4,282
4,432
4,536
4,432
5,361
5,607
5,991
- -
Depreciation Expense
3,950
3,112
4,441
7,324
10,179
8,764
9,360
8,198
5,714
7,257
7,544
6,679
12,157
13,641
14,301
7,531
6,951
Net Income, GAAP
18.92
17.44
17.98
17.37
17.48
16.9
14.14
13.43
1.14
13.04
7.57
19.93
16.99
8.77
13.53
12.41
10.39
Effective Tax Rate (%)
10.92
9.22
11.13
16.53
21.14
19.6
18.64
16.09
10.72
11.97
12.28
10.82
15.2
15.3
15.99
9.35
8.46
Profit Margin (%)
28,017
28,903
26,328
28,038
37,019
38,813
45,544
39,369
39,618
39,589
42,386
46,403
51,321
54,643
60,996
67,890
69,560
Working Capital
2,178
1,635
- -
- -
- -
- -
- -
- -
- -
393
267
139
4
379
268
139
108
LT Debt
49,447
51,904
55,062
62,172
70,851
78,173
83,888
90,931
95,185
101,245
107,484
113,196
123,277
134,895
146,506
152,350
153,786
Total Equity
6.5
5.56
7.97
13.01
14.79
11.47
10.97
9.06
6.38
8.27
5.98
5.78
9.54
9.84
9.32
4.33
4.05
Return on Invested Capital (%)
8
6.35
8.33
12.53
15.32
11.86
11.66
9.52
6.36
7.56
7.21
6.04
10.27
10.56
10.15
5.04
4.63
Return on Capital (%)
8.28
6.14
8.3
12.49
15.3
11.76
11.55
9.38
6.14
7.39
7.23
6.05
10.28
10.57
10.16
5.04
4.63
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
146
144
141
LT Borrowings
- -
- -
- -
LT Finance Leases
172
139
108
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
70,513
70,167
68,433

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
82,761
82,555
84,823
Cash, Cash Equivalents & STI
38,199
39,214
38,294
Accounts Receivable, Net
19,598
19,551
20,437
Inventories
24,006
23,009
25,329
Total Current Liabilities
14,711
14,665
15,263
Payables & Accruals
- -
- -
- -
ST Debt
146
144
141
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.92%
7.25%
3.99%
Free Cash Flow
65.42%
117.34%
-49.84%
Net Income, GAAP
3.53%
8.05%
-47.34%
Sales/Revenue/Turnover
6.54%
6.38%
-9.92%
Total Cash Common Dividend
- -
17.51%
11.76%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22,768
24,500
20,628
21,544
89,440
2025
19,249
19,558
20,621
21,136
80,564
2026
20,868
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
317
342
240
338.54
1,237
2025
174
240.06
225.55
11.5
651
2026
124.25
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
169.98
2025
- -
- -
- -
- -
189.86
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
SINIL PHARMACEUTICAL Co., Ltd. is a South Korea-based pharmaceutical company that develops, manufactures, and markets finished pharmaceutical formulations, over-the-counter medicines, functional cosmetics, and veterinary healthcare products. Founded in 1971 and incorporated in 1977, the company is headquartered in Chungju-si, Chungcheongbuk-do, South Korea, and is listed on the KOSDAQ under the ticker 012790. The company operates across multiple specialized product categories and therapeutic segments: topical pain relief and anti-inflammatory formulations, including transdermal drug delivery systems, nonsteroidal anti-inflammatory drug (NSAID) hydrogel cataplasms, and medicated adhesive plasters anchored by its flagship Defen Plaster (diclofenac sodium) brand family; prescription therapeutics (ETC), covering cardiovascular and metabolic agents, hyperlipidemia and antihypertensive treatments, antidiabetic formulations, gastrointestinal drugs, central nervous system medications, antihistamines, and respiratory remedies; over-the-counter (OTC) healthcare products, comprising oral analgesics, antipyretics, cough suppressants, topical dermatological treatments, cold remedies, and folic acid supplements; health functional foods and dietary nutritional supplements, including multivitamins and wellness products; derma-cosmetics and functional skincare formulations sold under its proprietary Farmtree brand; veterinary medicines for animal health management; and contract development and manufacturing organization (CDMO) and toll manufacturing services for domestic and international pharmaceutical partners. In recent developments, Sinil Pharmaceutical has strategically expanded its operational footprint and product portfolio to accelerate revenue growth and diversify beyond its traditional topical plaster foundation. The company has intensified its focus on ethical pharmaceuticals (ETC) by broadening its distribution networks through specialized contract sales organizations (CSOs) and advancing its internal research and development pipeline. Recent regulatory and commercialization milestones include the completion of development and rollout preparations for multi-drug prescription formulations, including antidiabetic combinations such as Forsigly Duo SR and Traglipitin, cardiovascular therapies including Aquis, and clinical pipeline candidates spanning hyperlipidemia (SIL1122), hypercholesterolemia (SIL1123), and rhinitis (SIL1406). Furthermore, the company has completed leadership succession and governance consolidation under Chief Executive Officer Jae-Hyun Hong and continues to optimize its Korea Good Manufacturing Practice (KGMP)-certified manufacturing and automated warehouse infrastructure in Chungju to expand output capacity for domestic distribution and global export markets.